Long-term legacy effects of LDL-C lowering with Alirocumab: observational follow-up of the ODYSSEY OUTCOMES study
ODYSSEY OUTCOMES clinical study includes patients who have consented to be followed for an additional period of up to 10 years of observational follow-up subsequent to completion of ODYSSEY OUTCOMES (the parent study). No study treatment will be provided and participants will be treated according to standard of care in their country/region. We will determine the long-term effects of Alirocumab treatment received in the double-blind treatment period over the extended observational period of up to 10 years.
Lucille Pierson, CCRP, CCRC; 425.467.3696; Lucille.firstname.lastname@example.org
Sanofi Aventis Group
Clinical Trial Categories